Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05677269

The (Cost-)Effectiveness of Surgical Excision of Colorectal Endometriosis Compared to ART Treatment Trajectory

To goal of this study is to determine whether laparoscopic resection of colorectal endometriosis results in an increased cumulative live birth rate (CLBR) both spontaneous and after ART (including in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI), and better patient reported outcome measures (PROMs) compared to an IVF/ICSI treatment trajectory.

Recruiting

Interested in participating?

Request Info

Key information

Age range

21 year–40 year

Sex eligibility

Female

Study type

Observational

Primary location

Catharina Ziekenhuis, Eindhoven, Netherlands

Loading trial locations.

About this study

Endometriosis is characterized by extra-uterine endometrium like tissue and affects 10-15% of the women in their reproductive years and in 5-12% of these women colorectal endometriosis is present. The quality of life is lowered due to severe pain symptoms (dysmenorrhea, dyschezia, dysuria, chronic pelvic pain) and subfertility.The management of colorectal endometriosis-related subfertility is challenging. While the impact of colorectal endometriosis per se remains inconclusive as other intraperitoneal endometriosis lesions are frequently present, fertility is most likely affected by multiple mechanisms including inflammatory alterations in peritoneal fluid, alterations in estrogen and progesterone hormone levels, lowered endometrium receptivity, associated adenomyosis, a lower ovarian reserve (in case endometriomas are present) and adhesion formation that disrupts adnexal anatomy and function. Usually, surgery is preferred in case of dominant pain complaints, while IVF/ICSI is started when the wish to conceive is dominant. Recent evidence suggests a CLBR of 44.9% in patients with rectosigmoid endometriosis treated by surgery compared to 55.9% after 4 cycles of IVF/ICSI treatment without surgery. In the Netherlands, the number of reimbursed IV/ICSI attempts in limited to three. In addition, a combined strategy may result in even higher cumulative live birth rates. However, the place and optimal timing of surgery in patients with colorectal endometriosis and a desire to have children is unknown.

To provide robust evidence that can be extrapolated to the Dutch healthcare system, this study aims to determine whether surgical excision of colorectal endometriosis results in increased CLBR both spontaneous and after IVF/ICSI, and better PROMs compared to an IVF/ICSI treatment trajectory.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Colorectal endometriosis defined as endometriosis involving the (colo)rectum:

#Enzian classification score C1,C2,C3 (C=rectum) or FI (F=far locations, I=sigmoid colon) detected with ultrasound or MRI;

  • Women in a heterosexual or in a same-sex relationship;
  • The patient has an active wish to conceive and experiences at least one of the following criteria:
  • At least one year of non-conception (either spontaneous of after intra uterine inseminations)
  • Inability to have timed intercourse because of pain (dyspareunia and/or chronic pelvic pain)
  • Severe complaints (expectant management is not acceptable (anymore)
  • The patients has an indication for IVF/ICSI according to Dutch guidelines (Werkgroep netwerkrichtlijn, december 2010);
  • failed intra uterine insemination
  • male factor subfertility (oligoasthenoteratozoospermia defined as VCM <1 million)
  • bilateral tubal pathology (e.g. bilateral hydrosalpinx, bilateral tubal occlusion)
  • age > 38 years and (unexplained) subfertility
  • severe endometriosis in case of subfertility
  • The patient is faces the choice between IVF/ICSI or laparoscopic (colorectal) endometriosis or is on the waiting list for a respective treatment at T=0 (at the beginning of the treatment trajectory), T=1 (after one unsuccessful IVF/ICSI cycle) or T=2 (after 2 unsuccessful IVF/ICSI cycles)

Exclusion criteria

  • Patients with deep endometriosis without colorectal involvement;
  • Patients who conceive spontaneously prior to intervention;
  • Patients requiring surgery on short notice and therefore unable to opt for IVF/ICSI (e.g. in case of unilateral or bilateral hydronephrosis, severe bowel stenosis and suspicion of an impending ileus);
  • Patients with a contra-indication for IVF/ICSI (e.g. diminished ovarian reserve (premature ovarian failure) (AMH (when available) <p10 adjusted for age), untreated congenital uterine abnormalities, maltreated/untreated systemic or malignant disease or severe risk factors for oocyte aspiration);
  • Patients diagnosed with other diseases causing infertility (e.g. recurrent miscarriages, antiphospholipid syndrome);
  • Not able to read and understand Dutch or English.

Treatment and study plan

Laparoscopic excision of endometriosis, including colorectal endometriosis

Procedure

Laparoscopic resection of deep endometriosis, including colorectal endometriosis, in a (candidate) level 2 centre of expertise. Complete resection can exist of either 'shaving' of the nodule from the bowel (leaving the lumen closed), discoid excision or segmental resection, depending on the nodule size and extent of disease.

In vitro fertilisation or intracytoplasmic sperm injection

Procedure

IVF/ICSI treatment trajectory (maximum of 3 cycles), according to the local protocol. Preferably preceded by 3 months downregulation with either Gonadotrophin-releasing hormone (GnRH) analogue or oral contraceptive pill. One IVF/ICSI cycle is defined as the transfer of all the embryos created after one follicle puncture until pregnancy confirmation or failure of the last embryo transfer.

Primary outcomes

  1. Cumulative live birth rate

    Time frame: At the end of the study period (live birth or after 3 IVF/ICSI attempts and/or surgery in the follow-up period (40 months) )

    Live birth is defined as the complete expulsion or extraction from a women of a product of fertilization, after 20 weeks of gestational age; which, after such separation, breathes or shows any other evidence of life, such as heart beat, umbilical cord pulsation or definite movement of voluntary muscles, irrespective of whether the umbilical cord has been cut of the placenta is attached. A birth weight of 350 grams or more can be used if gestational age is unknown

Secondary outcomes

  1. Endometriosis specific symptoms

    Time frame: At baseline (T=0: when informed consent is granted), 12, 24 and 36 months and in case of surgery, before surgery.

    Endometriosis Health Profile-30 (EHP-30). The overall EHP-30 score ranges from 0 to 100, with a high score indicating poorer health-related quality of life.

  2. Quality of life in general

    Time frame: At baseline (T=0: when informed consent is granted), 6, 12, 18, 24, 30, 36 and 40 months and in case of surgery, before surgery.

    EuroQql five-dimensional 5 levels (EQ-5D-5L) and EuroQql Visual Analog Scale (EQ-VAS).

    According to the Dutch scoring algorithm, the EQ-5D-5L score index value ranges from -0.446 (55555 worst health state) to 1 (11111, best health state).

    Overall health will be represented by the EQ-VAS, ranging from 0 to 100, with higher scores indicating better health.

  3. Bowel specific symptoms

    Time frame: At baseline (T=0: when informed consent is granted), 12, 24 and 36 months and in case of surgery, before surgery.

    Lower Anterior Resection Syndrome score (LARS score). The total LARS score ranges from 0, indicating no LARS to 42 points, indicating major LARS.

  4. Pain scores

    Time frame: At baseline (T=0: when informed consent is granted), 12, 24 and 36 months and in case of surgery, before surgery.

    NRS score for dysmenorrhea, dysuria, dyschezia, dyspareunia and chronic pelvic pain. The NRS scale ranges from 0 (no pain) to 10 (worst pain imaginable).

  5. Productivity costs

    Time frame: At baseline (T=6, 12, 18, 24, 30, 36 and 40 months and in case of surgery, before surgery.

    Productivity costs questionnaire: institute for Medical Technology Assessment (iMTA) Productivity Cost Questionnaire (iPCQ).

    Productivity costs will be measured by calculating absence from paid work (absenteeism), reduced productivity at paid work (presenteeism), and productivity loss in unpaid work. Hours of productivity loss will be translated by a standard cost price of productivity per hour.

  6. Medical costs per group

    Time frame: At the end of the study period (live birth or after 3 IVF/ICSI attempts and/or surgery in the follow-up period (40 months) )

    Costs surgery, costs IVF/ICSI treatment, costs extra hospital admissions / emergency room visits / visits outpatient care

  7. Complications

    Time frame: At the end of the study period (live birth or after 3 IVF/ICSI attempts and/or surgery in the follow-up period (40 months) )

    Intraoperative and postoperative complications, IVF/ICSI associated complications, pregnancy complications

Study contacts

Contact information is provided by the study sponsor or research team.

Mathijs D. Blikkendaal, MD,PhD

CONTACT

[email protected]

088 979 44 89

Rozemarijn de Koning, MD

CONTACT

[email protected]

Sponsors and collaborators

Lead sponsor

Leiden University Medical Center

Other

Collaborators

  • Catharina Ziekenhuis Eindhoven
  • Haaglanden Medical Centre
  • Maastricht University Medical Center
  • Radboud University Medical Center
  • Reinier de Graaf Groep
  • UMC Utrecht
  • University Medical Center Groningen

Registry information

Acronym: TOSCA

Important dates

Study start
2023
Primary completion
2028
Study completion
2029
First posted
Jan 10, 2023
Registry last updated
Nov 21, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.